News

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development ...
JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...
JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...
The huge premium drug maker Alexion Pharmaceuticals is paying for Synageva BioPharma—$8.4 billion, or more than double Synageva’s market value—shows how hot the market has become for rare ...
The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...
Is Alexion over-valued? I think its limited growth potential means the stock is dead money.
Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no ...
Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland's “first” complete transition to sustainable aviation fuel (SAF) for the international air delivery of ...
A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.
A former vice president at Alexion Pharmaceuticals pleaded guilty on Friday to one count of securities fraud for giving a friend an insider tip.